Tempus AI, Inc. is a technology company. The Company provides next generation diagnostics across multiple disease areas, with technology capabilities, harnessing the data and analytics to help personalize medicine. The Companyâs product lines include genomics, data, and artificial intelligence applications (AI). Its genomics product line leverages its laboratories to provide next generation sequencing, diagnostics, polymerase chain reaction (PCR), profiling, molecular genotyping, and other anatomic and molecular pathology testing. The Company's AI applications are focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools. Its primary product of AI applications is Next, an AI platform that leverages machine learning to apply an intelligent layer onto routinely generated data to proactively identify and minimize care gaps for oncology and cardiology patients.
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļTEM
āļāļ·āđāļāļāļĢāļīāļĐāļąāļTempus AI Inc
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļJun 14, 2024
āļāļĩāļāļĩāđāļMr. Eric P. Lefkofsky, J.D.
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ2400
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļJun 14
āļāļĩāđāļāļĒāļđāđ600 West Chicago Avenue
āđāļĄāļ·āļāļCHICAGO
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ Global Select Consolidated
āļāļĢāļ°āđāļāļĻUnited States of America
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ60654
āđāļāļĢāļĻāļąāļāļāđ18009765448
āđāļ§āđāļāđāļāļāđhttps://www.tempus.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļTEM
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļJun 14, 2024
āļāļĩāļāļĩāđāļMr. Eric P. Lefkofsky, J.D.
Mr. Ryan Fukushima
Chief Operating Officer
Mr. Peter J. Barris
Independent Director
Mr. Eric D. Belcher
Independent Director
Mr. Andrew (Andy) Polovin
Mr. Andrew (Andy) Polovin
Executive Vice President, General Counsel, Company Secretary
Executive Vice President, General Counsel, Company Secretary
Mr. James (Jim) Rogers
Chief Financial Officer
Mr. David R. Epstein
Independent Director
Dr. Scott Gottlieb, M.D.
Independent Director
Dr. Jennifer A. Doudna, Ph.D.
Dr. Jennifer A. Doudna, Ph.D.
Independent Director
Mr. Theodore John (Ted) Leonsis
Mr. Theodore John (Ted) Leonsis
Independent Director
Dr. Nadja Y. West, M.D.
Independent Director
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Mr. Ryan Fukushima
Chief Operating Officer
Mr. Peter J. Barris
Independent Director
Mr. Eric D. Belcher
Independent Director
Mr. Andrew (Andy) Polovin
Mr. Andrew (Andy) Polovin
Executive Vice President, General Counsel, Company Secretary
Executive Vice President, General Counsel, Company Secretary
Mr. James (Jim) Rogers
Chief Financial Officer
Mr. David R. Epstein
Independent Director
ARK Genomic Revolution ETF
Franklin Genomic Advancements ETF
KraneShares Artificial Intelligence and Tcnlgy ETF
First Trust Health Care Alphadex Fund
ROBO Global Artificial Intelligence ETF
ROBO Global Healthcare Technology & Innovation ETF
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
ARK Genomic Revolution ETF
āļŠāļąāļāļŠāđāļ§āļ10.53%
Global X HealthTech ETF
āļŠāļąāļāļŠāđāļ§āļ6.29%
ARK Innovation ETF
āļŠāļąāļāļŠāđāļ§āļ5.71%
Renaissance IPO ETF
āļŠāļąāļāļŠāđāļ§āļ3.91%
Franklin Genomic Advancements ETF
āļŠāļąāļāļŠāđāļ§āļ3.64%
KraneShares Artificial Intelligence and Tcnlgy ETF
āļŠāļąāļāļŠāđāļ§āļ3.46%
First Trust Health Care Alphadex Fund
āļŠāļąāļāļŠāđāļ§āļ2.69%
AXS Green Alpha ETF
āļŠāļąāļāļŠāđāļ§āļ2.55%
ROBO Global Artificial Intelligence ETF
āļŠāļąāļāļŠāđāļ§āļ2.51%
ROBO Global Healthcare Technology & Innovation ETF
āļŠāļąāļāļŠāđāļ§āļ1.94%
āļĄāļĩāļāļēāļĢāļāđāļēāļĒāđāļāļīāļāļāļąāļāļāļĨāđāļāđāļāļāļģāļāļ§āļāļĢāļ§āļĄ
0.00
USD āđāļāļāđāļ§āļ 5 āļāļĩāļāļĩāđāļāđāļēāļāļĄāļē

āđāļĄāđāļĄāļĩāļāđāļāļĄāļđāļĨ